

RECEIVED
CENTRAL FAX CENTER

OCT 17 2006

Attorney Docket No. 397037

AMENDMENTS TO THE CLAIMS:

1. (Previously presented) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:
8-hydroxyquinoline in an amount of at least five percent of the composition by weight;
an escharotic chelatable metal agent bonded to said 8-hydroxyquinoline, the escharotic chelatable metal agent comprising a metal having an oxidation state of +2 present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and
a carrier,
the composition being a pharmaceutical grade material having a capacity for treating at least one type of lesion selected from the group consisting of venereal warts, male verruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.
2. (Previously presented) The composition as set forth in claim 1, wherein the escharotic chelatable metal agent includes zinc in a molar ratio (8-hydroxyquinoline:zinc) ranging from 1:1 to 1:3.
3. (Previously presented) The composition as set forth in claim 2 wherein said molar ratio is about 1:2.
4. (Previously Amended) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc.
5. (Previously presented) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount ranging up to forty percent by weight of said composition by weight.

Application Serial No.: 09/021,421

2

Attorney Docket No. 397037

6. (Previously presented) The composition as set forth in claim 1 wherein said escharotic chelatable metal agent comprises zinc chloride in an amount ranging up to twenty percent of said composition by weight.

7. (Previously presented) The composition as set forth in claim 1 in combination with necrotic tissue from a lesion of said group produced by the action of said composition upon the lesion.

8-13. (Cancelled.)

14. (Previously presented) The composition as set forth in claim 1, wherein said carrier comprises a gel.

15. (Previously presented) The composition as set forth in claim 14 wherein said gel comprises a polyoxyalkylene ether derivative of propylene glycol.

16. (Original) The composition as set forth in claim 1 wherein said carrier contains a penetrant.

17. (Original) The composition as set forth in claim 1 wherein said penetrant is lecithin.

18. (Original) The composition as set forth in claim 1 wherein said penetrant is dimethyl sulfoxide.

19. (Currently Amended) The composition as set forth in claim 1 wherein said carrier contains ~~means for functioning as an~~ antioxidant.

20. (Previously presented) The composition as set forth in claim 19 wherein said antioxidant includes nordihydroguaiaretic acid.

21. (Previously presented) The composition as set forth in claim 19 wherein said antioxidant includes ascorbic acid.

22-33 (Cancelled)

Application Serial No.: 09/021,421

Attorney Docket No.397037

34. (Original) The composition as set forth in claim 1 wherein said carrier consists essentially of an antioxidant.

35. (Original) The composition as set forth in claim 34 wherein said antioxidant consists essentially of an ascorbate.

36. (Original) The composition as set forth in claim 34 wherein the antioxidant consists essentially of nordihydroguaiaretic acid.

37-38 (Cancelled)

39. (Previously presented) A composition for use in treating epithelial lesions formed of a combination of ingredients comprising:

8-hydroxyquinoline in an amount of at least five percent of the composition by weight;

zinc chloride present in a concentration of at least five percent by weight of the composition and less than an amount that produces an eschar in healthy mammalian tissues; and

a carrier.

40. (Currently amended) The composition of claim 39, the 8-hydroxyquinoline and the zinc chloride being present in effective amounts for treating at least one type of lesion selected from the group consisting of venereal warts, male veruoca warts, lesions produced by the human papilloma virus, basal cell carcinoma, solar keratosis, Kaposi's sarcoma, eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histiocytoma, sebaceous adenoma, lung cancer, breast cancer, and colon cancer.

41. (Currently amended) The composition as set forth in claim 39, wherein the 8-hydroxyquinoline and the zinc chloride are present in a molar ratio (8-hydroxyquinoline:zinc) ranging from 1:1 to 1:3 ~~by weight~~.

42. (Currently amended) The composition as set forth in claim 41, wherein the molar ratio is about 1:2.

Application Serial No.: 09/021,421

4

Attorney Docket No.397037

43. (Currently Amended) The composition as set forth in claim 41, wherein the ~~8-hydroxyquinoline~~ 8-hydroxyquinoline is present in an amount ranging up to twenty percent.

44. (Previously Presented) The composition as set forth in claim 39 in combination with necrotic tissue from a lesion of said group produced by the action of the composition upon the lesion.

45. (Previously Presented) The composition as set forth in claim 39, wherein the carrier is a gel base.

46. (Previously Presented) The composition as set forth in claim 45, wherein the gel base is a polyoxyalkylene ether derivative of propylene glycol.

47. (Previously Presented) The composition as set forth in claim 39, wherein the carrier contains a penetrant.

48. (Previously Presented) The composition as set forth in claim 39, wherein the penetrant is lecithin.

49. (Previously Presented) The composition as set forth in claim 39, wherein the penetrant is dimethyl sulfoxide.

50. (Previously Presented) The composition as set forth in claim 39, wherein the carrier contains an antioxidant.

51-52 (Cancelled)

Application Serial No.: 09/021,421

5